目的:产品信息和文献未证实所有常用药物对在产科共同给药的相容性。然而,对于这组患者,需要在一个管腔内共同施用这些药物.因此,这项研究的重点是Y位点兼容性。由于临床和实验室设置之间的不同条件会导致结果差异,设计了一种新的药物静脉相容性测试方法来反映临床情况.目的研究产科9种常用药物对的相容性,并评价所设计方法的临床价值。
方法:通过使用不同的温度范围(20°C和37°C)来反映临床情况,实际Y站点流量比,临床相关药物对和120分钟的观察时间。临床相关药物对包括阿托西班,尼卡地平,阿莫西林/克拉维酸,催产素,瑞芬太尼,拉贝洛尔和硫酸镁。根据欧洲药典(Ph。欧尔.)和测量pH。当根据文献综述或在视觉评估期间观察到的异常似乎可能出现药物对的不相容性时,使用粒子计数器进行亚视觉分析.当在观察时间期间没有发生视觉变化或没有形成额外的颗粒时,Y-位点相容性应用于药物对。
结果:9种组合中的8种在观察时间内没有视觉变化或pH明显变化。阿莫西林/克拉维酸-催产素组合在37°C时在实际Y位点流量比下显示颜色变化。然而,亚视觉颗粒计数显示没有形成额外的颗粒。
结论:对所有测试的药物对都建立了Y位点相容性。分析Y位点相容性的新临床方法为临床实践提供了高度确定性的结果。这样,可以避免临床并发症和使用额外的静脉导管.
OBJECTIVE: The product information and literature does not provide confirmation of compatibility for co-administration of all commonly used drug pairs in obstetrics. However, there is a need for co-administration of these drugs over one lumen for this group of patients. Therefore, this study focuses on Y-site compatibility. Since different conditions between clinical and laboratory settings can lead to discrepancies in results, a novel approach for drug intravenous compatibility testing was designed to reflect clinical conditions. The aim was to study the compatibility of nine commonly used drug pairs in obstetrics and to evaluate the clinical value of the designed method.
METHODS: The clinical situation was reflected by using different temperature ranges (20°C and 37°C), actual Y-site flow ratios, clinically relevant drug pairs and an observation time of 120 min. The clinically relevant drugs pairs include atosiban, nicardipine, amoxicillin/clavulanic acid, oxytocin, remifentanil, labetalol and magnesium sulpfate. Drug pairs were visually assessed according to the European Pharmacopoeia (Ph. Eur.) and pH was measured. When incompatibility of a drug pair seemed likely based on literature review or observed abnormalities during visual assessment, subvisual analysis was performed using a particle counter. Y-site compatibility applied for drug pairs when no visual changes occurred or when no additional particles were formed during the observation time.
RESULTS: Eight of the nine combinations showed no visual changes or noticeable changes in pH during the observation time. The amoxicillin/clavulanic-acid-oxytocin combination showed a colour change at 37°C at the actual Y-site flow ratio. However, subvisual particle counting showed no formation of additional particles.
CONCLUSIONS: Y-site compatibility was established for all tested drug pairs. The new clinical approach for analysing Y-site compatibility provides a high certainty of outcomes for clinical practice. In this way, clinical complications and use of several additional intravenous catheters can be avoided.